Clinical Trial Detail

NCT ID NCT03968419
Title This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Canakinumab

Pembrolizumab

Canakinumab + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.